Outcomes of Abrupt Switch to Bevacizumab of Patients Undergoing Aflibercept Intravitreal Injections for Neovascular Age-Related Macular Degeneration in a Tertiary Center in Lombardy, Italy: A Real-Life Retrospective Analysis. (11th September 2021)

• Record Type: Journal Article
• Authors: Randazzo, Alessandro; Raimondi, Raffaele; Fossati, Giovanni; Romano, Mary; Sorrentino, Tania; Castellani, Carlo; Rossi, Costanza; Cancian, Giuseppe; Vinciguerra, Paolo
• Other Names: Oishi Akio Academic Editor.
• Is Part Of: Journal of ophthalmology. Volume 2021(2021)
• Publication Date: 2021-09-11
• Subjects: Ophthalmology -- Periodicals; Eye Diseases; Ophthalmology; Ophthalmology; Electronic journals; Periodicals; Periodicals; Fulltext; Internet Resources; Periodicals; 617.7
• DOI: 10.1155/2021/7940297
• Languages: English
• ISSNs: 2090-004X

Abstract

Abstract : Purpose . To assess real-life anatomical and functional outcomes of switch to bevacizumab in patients undergoing aflibercept intravitreal injections for nAMD. Methods . Retrospective chart review of all patients diagnosed with nAMD and undergoing intravitreal injections of aflibercept who switched to bevacizumab after the resolution XI/1986 of Lombardy Region. Results . Among 128 patients undergoing intravitreal injections, a total of 29 eyes of 29 patients met all inclusion criteria and were included in the statistical analysis. Best corrected visual acuity and central macular thickness did not change significantly (p > 0.05 ) between baseline, after the loading phase, and at the last follow-up. Conclusion . Switching to bevacizumab has been safe and efficacious in patients responding to the loading phase. According to our results, the restrictions imposed by Lombardy Region did not cause any harm to patients undergoing intravitreal anti-VEGF injections.